Latest News, Grants & Research Reports
Read our latest news, blog posts and research updates right here
SIOPEN High-Risk Neuroblastoma Study 2: Progress Update
The trial is sponsored and centrally coordinated by Institute Gustave Roussy in Paris and is currently open to recruitment in 17 countries. The trial is open and recruiting in 20 of 21 UK children’s oncology centres apart from one.
Clinical trial for children with high-risk neuroblastoma open
We are delighted to share that the SIOPEN High-Risk Neuroblastoma 2 trial is now officially open and ready to recruit at its first UK hospital, with more to follow soon.
In May 2020, we announced the award of £609, 762 in partnership with Solving Kids Cancer to open the UK sites of the SIOPEN High-Risk Neuroblastoma 2 trial. This latest European-wide study will look to answer important questions about the standard care protocols for children with high-risk neuroblastoma, and how they might be improved.
SIOPEN High-Risk Neuroblastoma Clinical Trial 2 to open in the UK in 2021
Neuroblastoma UK with Solving Kids’ Cancer has awarded a grant of £609,762.40 to enable the SIOPEN High-Risk Neuroblastoma Clinical Trial 2 (HR-NBL2) to open in the UK. The trial is anticipated to open in early 2021.
This Phase 3 clinical trial will offer children in the UK, with a diagnosis of high-risk neuroblastoma, to have the same opportunities as children across Europe and take part in this pan-European study, enabling a series of important randomised questions to be answered within the overall framework of the trial.
Press release: Charities fund new clinical trial to help children with cancer
Neuroblastoma UK and Solving Kids Cancer have awarded a grant to enable the SIOPEN High-Risk Neuroblastoma Clinical Trial 2 (HR-NBL2) to open in the UK, it is anticipated to open in early 2021.
This Phase 3 clinical trial will offer children in the UK, with a diagnosis of high-risk neuroblastoma, to have the same opportunities as children across Europe and take part in this pan-European study.